Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CBP-174 · 1 trial · 1 indication
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) Dictionary.
The investigator may use the CTCAE V5.0 to assist in the determination of severity and clinical significance.
Blood pressure measured in mmHg
Pulse rate measured per minute
respiratory rate measured in breaths per minute
tympanic temperature measured in celsius
Physical examinations includes examination in cutaneous, lymph node, head (especially of eyes) and neck, chest, abdomen, musculoskeletal and nervous systems.
Heart rate in beats per minute (Bpm) through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
R-R interval measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
P-R interval measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
QRS complex measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
QT interval measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
QTcF interval measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
Measured in g/dL. The physician will judge whether an abnormality is clinically significant.
Measured in g/dL. The physician will judge whether an abnormality is clinically significant.
Measured in IU/L. The physician will judge whether an abnormality is clinically significant.
Measured in IU/L. The physician will judge whether an abnormality is clinically significant.
Measured in IU/L. The physician will judge whether an abnormality is clinically significant.
Measured in U/L. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in IU/L. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/L. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/L. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in %. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Urine Occult Blood will be record as positive or negative. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Urinary leukocyte will be counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Urine erythrocytes will be counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in seconds by coagulation tests. The physician will judge whether an abnormality is clinically significant.
Measured in seconds by coagulation tests. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Measured in mmol/L. The physician will judge whether an abnormality is clinically significant.
Measured in seconds by coagulation tests. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Measured in Units. The physician will judge whether an abnormality is clinically significant.
Measured in Units. The physician will judge whether an abnormality is clinically significant.
Recorded as positive or negative. The physician will judge whether an abnormality is clinically significant.
| Arm | Type | Description |
|---|---|---|
| CBP-174 | EXPERIMENTAL | CBP-174 oral solution |
| Placebo | EXPERIMENTAL | placebo oral solution |
| Name | Type | Description |
|---|---|---|
| CBP-174 | DRUG | CBP-174 oral solution, given once |
| Placebo | DRUG | Placebo oral solution, given once |
Inclusion Criteria: Subjects will be enrolled into the study only if they meet ALL of the following inclusion criteria: 1. Subjects are fully informed of the study, and are willing to participate in the study and sign the informed consent document prior to any procedure 2. Healthy male and female ...
CBP-174 is an investigational small molecule drug being developed by Connect Biopharma Holdings Limited. It has completed a Phase 1 clinical trial in healthy adult volunteers. Its therapeutic indications have not been disclosed, so it is not yet associated with a specific disease area in public disclosures.
CBP-174 targets the H3 receptor, also known as H3R, a receptor class molecular target. It is a small molecule designed to act on this receptor. Targeting H3R places CBP-174 among compounds that modulate histamine H3 receptor signaling, though its specific clinical application remains undisclosed.
CBP-174 is being developed by Connect Biopharma Holdings Limited, which trades under the ticker CNTB. The company is the sponsor of the drug's clinical program. Connect Biopharma is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune conditions.
CBP-174 is in Phase 1 development. It has completed one Phase 1 clinical trial and has no active trials at this time. As an investigational drug, CBP-174 has not been approved by the FDA or any other regulatory authority for commercial use.
CBP-174 has been studied in one completed Phase 1 trial, NCT04811469, titled Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults. The trial enrolled 74 healthy adult volunteers in Australia, was randomized, double-blind, and controlled, and included participants aged 18 years and older.